Successful treatment of a recurrent Aspergillus niger otomycosis with local application of voriconazole

被引:16
作者
Chappe, M. [1 ]
Vrignaud, S. [1 ]
de Gentile, L. [2 ]
Legrand, G. [3 ]
Lagarce, F. [1 ,4 ]
Le Govic, Y. [2 ,5 ]
机构
[1] CHU Angers, Pharm Cent, F-49933 Angers, France
[2] CHU Angers, Lab Parasitol Mycol, F-49933 Angers, France
[3] Clin Anjou, Cabinet Otorhinolaryngol, F-49000 Angers, France
[4] Univ Bretagne Loire, Inserm U1066, CNRS 6021, Micro & Nanomed Biomimet, F-49933 Angers, France
[5] Univ Bretagne Loire, EA 3142, Grp Etud Interact Hote Pathogene, F-499333 Angers, France
来源
JOURNAL DE MYCOLOGIE MEDICALE | 2018年 / 28卷 / 02期
关键词
Aspergillus niger; Otomycosis; Otitis externa; Voriconazole; Nystatin; AMPHOTERICIN-B; ITRACONAZOLE; SUSCEPTIBILITIES; TERBINAFINE; AGENTS; SPP;
D O I
10.1016/j.mycmed.2018.03.009
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Fungal otitis (otomycosis) is a common infection encountered by otolaryngologists. Nevertheless, its management can be challenging because of its high recurrence rate and of the limited therapeutic options. A 45-year-old woman suffered from recurrent otomycosis. The ineffectiveness of successive antibiotic cures and repeated topical treatments with nystatin and then with econazole cream led to perform microbiological analyses. Culture of ear swab grew Aspergillus niger. The use of a 1% voriconazole sterile solution previously validated for treatment of eye infections was considered after ensuring the absence of known ototoxic effects of the antifungal and of the excipients. The patient was advised to apply locally this voriconazole solution daily for 14 days (3 drops, 3-4 times a day). Full recovery was obtained at the end of the treatment, and no relevant side effects were noticed. More than one year after completion of therapy, there was no recurrence. Our observation shows that voriconazole 1% solution is an interesting option for treating otomycosis which failed to respond to usual therapeutic options. Further prospective studies are now warranted to confirm these findings. (C) 2018 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:396 / 398
页数:3
相关论文
共 22 条
[1]   Ototoxic Effect of Topical Oxiconazole and Terbinafine in Rats [J].
Aydin, Emine ;
Tastan, Eren ;
Aydogan, Filiz ;
Karaca, Gokhan ;
Safak, Mustafa Asim .
JOURNAL OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2012, 41 (02) :78-83
[2]   BROAD-SPECTRUM ANTIFUNGAL AGENTS IN OTOMYCOSIS [J].
BASSIOUNY, A ;
KAMEL, T ;
MOAWAD, MK ;
HINDAWY, DS .
JOURNAL OF LARYNGOLOGY AND OTOLOGY, 1986, 100 (08) :867-873
[3]  
Council of Europe, 2017, EUR PHARMACOPOEIA, V90, P855
[4]  
de Hoog G.S., 2000, ATLAS CLIN FUNGI, V2nd, P1124
[5]   Randomized prospective comparative study:: short-term treatment with ciclopiroxolamine (cream and solution) versus boric acid in the treatment of otomycosis [J].
del Palacio, A ;
Cuétara, MS ;
López-Suso, MJ ;
Amor, E ;
Garau, M .
MYCOSES, 2002, 45 (08) :317-328
[6]  
DELPALACIO A, 1993, J MED VET MYCOL, V31, P435
[7]   Preparation and Stability of Voriconazole Eye Drop Solution [J].
Dupuis, Antoine ;
Tournier, Nicolas ;
Le Moal, Gwenael ;
Venisse, Nicolas .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (02) :798-799
[8]   Wild-Type MIC Distributions and Epidemiological Cutoff Values for Amphotericin B and Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document) [J].
Espinel-Ingroff, A. ;
Cuenca-Estrella, M. ;
Fothergill, A. ;
Fuller, J. ;
Ghannoum, M. ;
Johnson, E. ;
Pelaez, T. ;
Pfaller, M. A. ;
Turnidge, J. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (11) :5150-5154
[9]   Treatment of refractory Aspergillus otomycosis with voriconazole: case series and review [J].
Ho, Hsu-Chueh ;
Hsiao, Shih-Hsuan ;
Lee, Cheng-Yung ;
Tsai, Chen-Chi .
JOURNAL OF LARYNGOLOGY AND OTOLOGY, 2014, 128 (06) :547-551
[10]   Otomycosis: Clinical features and treatment implications [J].
Ho, Tang ;
Vrabec, Jeffrey T. ;
Yoo, Donald ;
Coker, Newton J. .
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2006, 135 (05) :787-791